LianBio (LIAN) Competitors

Lyell Immunopharma (NASDAQ:LYEL) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, community ranking, institutional ownership, valuation, earnings, risk, profitability and dividends.

Do analysts recommend LYEL or LIAN?

Lyell Immunopharma currently has a consensus price target of $20.00, suggesting a potential upside of 105.34%. Given Lyell Immunopharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Lyell Immunopharma is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Which has more volatility & risk, LYEL or LIAN?

Lyell Immunopharma has a beta of -0.26, indicating that its share price is 126% less volatile than the S&P 500. Comparatively, LianBio has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500.

Does the media favor LYEL or LIAN?

In the previous week, Lyell Immunopharma had 7 more articles in the media than LianBio. MarketBeat recorded 7 mentions for Lyell Immunopharma and 0 mentions for LianBio. Lyell Immunopharma's average media sentiment score of 0.66 beat LianBio's score of 0.00 indicating that Lyell Immunopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Lyell Immunopharma	Positive
LianBio	Neutral

Is LYEL or LIAN more profitable?

LianBio has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -323,792.09%. LianBio's return on equity of -33.17% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-323,792.09%	-34.64%	-30.02%
LianBio	N/A	-33.17%	-30.19%

Do insiders & institutionals have more ownership in LYEL or LIAN?

66.1% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 74.8% of LianBio shares are owned by institutional investors. 25.1% of Lyell Immunopharma shares are owned by company insiders. Comparatively, 7.6% of LianBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Does the MarketBeat Community favor LYEL or LIAN?

Lyell Immunopharma received 10 more outperform votes than LianBio when rated by MarketBeat users. Likewise, 43.75% of users gave Lyell Immunopharma an outperform vote while only 36.36% of users gave LianBio an outperform vote.

Company	Underperform	Outperform
Lyell Immunopharma	Outperform Votes 14 43.75%	Underperform Votes 18 56.25%
LianBio	Outperform Votes 4 36.36%	Underperform Votes 7 63.64%

Which has higher earnings & valuation, LYEL or LIAN?

LianBio has lower revenue, but higher earnings than Lyell Immunopharma. LianBio is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$65K	2,218.92	-$234.63M	-$25.00	-0.39
LianBio	N/A	N/A	-$110.29M	-$0.81	-0.46

Summary

Lyell Immunopharma beats LianBio on 9 of the 16 factors compared between the two stocks.